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Background. Patients have been described who have
both anti-neutrophil cytoplasm antibodies (ANCA) and anti-
glomerular basement membrane (GBM) antibodies. We have
attempted to define the true prevalence of such “double posi-
tive” patients, and describe in detail their clinical features and
outcome.
Methods. We have reviewed all serologic assays performed
between 1990 and 2000 in a single institution, and the case notes
of patients having sera positive for both ANCA and anti-GBM
antibodies. During this time 20,392 sera were initially tested for
ANCA, and 4808 sera tested for anti-GBM antibodies.
Results. Five percent of all ANCA-positive serum samples
were also positive for anti-GBM antibodies, and 32% of all anti-
GBM positive samples had detectable ANCA. Of 27 patients
with both antibodies, 82% had anti-myeloperoxidase specific P-
ANCA. Pulmonary hemorrhage occurred in 44%. Renal biopsy
showed extensive glomerular cellular crescents in most patients.
Patient and renal survival rates were 52% and 26%, respec-
tively, at one year. Sixty-eight percent of patients were dialysis-
dependent at presentation, and none of these recovered renal
function, despite immunosuppression with or without plasma
exchange.
Conclusion. Serologic evidence of double positivity for both
ANCA and anti-GBM antibodies is common in patients with ei-
ther antibody. In our study these patients have a poor prognosis
when presenting with severe disease and initially behave more
like anti-GBM disease than vasculitis. Recovery from severe
renal failure is rare.
Anti-glomerular basement membrane (anti-GBM)
disease and anti-neutrophil cytoplasm antibody (ANCA)
associated vasculitis are both characterized by circulat-
ing autoantibodies. Anti-GBM antibodies are undoubt-
edly pathogenic and can transfer disease in experimental
models. Their removal by plasma exchange and immuno-
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suppression can lead to recovery of renal function in
patients treated before renal damage is too severe [1].
The target antigen for anti-GBM antibodies is the alpha
3 chain of type IV collagen, and, more precisely, epi-
tope(s) in its NC1 domain [2]. All patients with anti-GBM
antibody–induced disease have circulating or deposited
antibody. In contrast, ANCA include two distinct pop-
ulations of antibodies, which either bind to myeloper-
oxidase (P-ANCA; MPO-ANCA) or proteinase 3
(C-ANCA; PR3-ANCA), and which are generally
associated with microscopic polyangiitis and We-
gener’s granulomatosis, respectively. Whether ANCA are
pathogenic in these vasculitides has been debated, but
there is strong evidence of pathogenicity from in vitro
studies, and recent work in animal models has shown that
transfer of MPO-ANCA can cause renal disease [3].
A number of patients have been reported in whom both
sets of autoantibodies coexist. Usually both antibodies
are found at the time of clinical presentation in a patient
with a rapidly progressive crescentic glomerulonephritis,
and it is unclear which is the primary contributor to re-
nal damage. The frequency of such “double positive” pa-
tients has not been ascertained, and the clinical outcome
of these patients remains poorly defined. O’Donaghue
reported three patients with both antibodies, all of whom
remained dialysis-dependent despite treatment [4]. Jayne
et al attempted to define the approximate frequency of
the association [5], and suggested that 30% of patients
with anti-GBM antibodies had ANCA, and 7.5% of those
with ANCA had anti-GBM antibodies. In this small se-
ries, 3 of 7 treated patients with severe renal failure recov-
ered renal function. Hellmark et al performed a detailed
analysis of serum samples, and documented 38% of sam-
ples with anti-GBM antibodies as having ANCA, and
14% of those with ANCA as having anti-GBM antibod-
ies [6]. Short et al and Weber et al reported similar results
in small numbers of patients [7, 8]. Outcomes in patients
with severe disease have generally been poor; Denton et
al and Bonsib et al reported that most patients died or re-
mained dialysis-dependent [9, 10]. In contrast, Bosch et al
suggested that patients with MPO-ANCA and anti-GBM
antibodies responded better to therapy [11] than patients
1535
1536 Levy et al: Double positive disease
with isolated anti-GBM antibodies. The most recent re-
port from Sweden identified 29 patients from a cohort
of those with anti-GBM antibodies who also had ANCA
antibodies [12]. The majority had anti-MPO P-ANCA,
but their outcome was better than those with anti-GBM
antibodies alone.
We have determined the prevalence of patients with
both types of autoantibody in a large series detected by
our assay service, and describe their clinical and serologic
features, and their clinical outcome.
METHODS
Our laboratory performs ANCA and anti-GBM anti-
body testing for a number of hospitals in West London,
and acts as a reference laboratory more widely for diffi-
cult cases. All patients identified in our laboratory as hav-
ing either anti-GBM antibodies or ANCA from 1990 to
2000 were identified from our records of serologic testing.
ANCA assays were performed by indirect immunoflu-
orescence using ethanol-fixed human neutrophils, and
enzyme-linked immunosorbent assays (ELISA) against
purified MPO and PR3. Anti-GBM assays were per-
formed by ELISA using collagenase-solubilized sheep
glomerular basement membrane, with confirmation of
antibody specificity by Western blot against purified
GBM. Sera were only considered true double-positive if
they bound the monomer and dimer NC1 bands contain-
ing the alpha 3 chain of type IV collagen. Confirmation
of specificity of binding was obtained by an inhibition
assay; Western blots of human GBM were preincubated
with a saturating concentration of murine monoclonal
antibody P1 [13] prior to addition of human serum [14].
Serum binding was detected using specific antihuman IgG
antibody-conjugates. Clinical details were obtained by re-
view of notes. Although all patients’ sera were tested in
our laboratory, some patients had been treated in the
referring hospital. This study was approved by the Ham-
mersmith Hospital Research Ethics Committee.
RESULTS
In our laboratory, 20,392 individual patients’ samples
were tested for ANCA between 1990 and 2000. Of these,
954 (4.7%) were positive for ANCA (P or C-ANCA).
Five percent of the ANCA-positive sera also had a de-
tectable anti-GBM antibody. Four thousand eight hun-
dred and eight individual patients’ serum were initially
tested for anti-GBM antibodies, of which 121 (2.5%)
were positive. Thirty-nine of these (32%) had detectable
ANCA. Twenty-seven of the double-positive patients
(69%) had anti-GBM antibodies indistinguishable from
those in patients with isolated anti-GBM disease, and
bound the alpha 3 chain of type IV collagen when tested
by Western blot against purified human GBM. This was
Table 1. Clinical features of double-positive patients
Clinical feature Number %
Renal disease 27 (100)
Malaise and general weakness 12 (44)
Pulmonary hemorrhage 11 (41)
Rash 6 (22)
Other respiratory symptoms 5 (19)
ENT/sinus symptoms 3 (11)
Painful/red eyes 2 (7)
Table 2. Laboratory features of double-positive patients
Laboratory test Median (range)
Creatinine 636 lmol/L (71–1600)
Hemoglobin 10.4 g/dL (6.9–13.6)
CRP 36 mg/dL (2–280)
Albumin 36 g/L (24–40)
confirmed by inhibition of binding of double-positive sera
to human antigen by the monoclonal antibody P1 in West-
ern blot assay [13]. The remaining 12 patients (31%) had
anti-GBM antibodies that bound other components of
glomerular basement membrane, but not to the alpha 3
chain of type IV collagen; these patients were considered
not to have true double-positive disease (see later).
The true double-positive patients had a median age of
66 years (range 16 to 79), and 13 were men. They pre-
sented a mean of 26 weeks after first symptoms, and 41%
had pulmonary hemorrhage. Clinical features at presen-
tation are shown in Table 1, and laboratory features in
Table 2. One patient was HIV positive.
All 27 patients had haematuria and proteinuria, 10
(37%) had serum creatinine less than 500 lmol/L at pre-
sentation, and 19 (70%) required dialysis with 48 hours.
All patients had detectable circulating anti-GBM anti-
bodies, with a median level of 50% in our assay (range
22% to 96%). Two of these patients had a C-ANCA pat-
tern, three an atypical pattern, and the remainder [22], a
P-ANCA pattern by immunofluorescence. All three pa-
tients with an atypical pattern had both anti-MPO and
anti-PR3 antibodies by ELISA (with levels 20% to 40%).
One of the patients with C-ANCA had a pure anti-PR3
antibody, and the other had both anti-PR3 and anti-MPO
antibodies. All patients with P-ANCA (81%) had anti-
bodies binding MPO, with a median titre of 43% (range
19% to 100%). There was a broad correlation between
anti-GBM and ANCA titres overall (Fig. 1; r2 = 0.14,
P = 0.02). Both ANCA and anti-GBM antibody titres
fell to normal levels within 2 months of treatment in most
patients (Fig. 2), and subsequently remained low or unde-
tectable up to 10 years later. No patient had antinuclear
antibodies, and all had normal serum complement levels.
Renal biopsy was performed in 22 patients. All but
two had crescentic glomerulonephritis, with median cres-
cent score of 84% (range 0% to 100%), most crescents
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Fig. 1. Relationship between titres of serum anti-neutrophil cytoplasm
antibodies (ANCA) and anti-GBM antibodies (overall r2 = 0.14, P =
0.02). ∗Patients not requiring dialysis at presentation.
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Fig. 2. Serial changes in anti-neutrophil cytoplasm antibodies
(ANCA) and anti-GBM antibody levels in double-positive patients.
being cellular rather than fibrotic. Glomerular fibrinoid
necrosis was evident in 14 biopsies (64%), interstitial in-
filtrates in 10 (45%), tubular atrophy in 8 (36%), and
overt vasculitis (as shown by intrarenal arteritis with fib-
rinoid necrosis in the artery wall) in 7 (32%). All biopsies
examined by immunohistology showed linear deposition
of IgG and C3, but additionally, four biopsies had some
granular deposition of IgG, IgM, and C3. The one patient
with HIV did not have a crescentic glomerulonephritis,
but only a mild interstitial infiltrate on his renal biopsy.
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Fig. 3. Relationship between serum creatinine and crescent score.
∗Patients not requiring dialysis at presentation.
Table 3. Complications from immunosuppression in double-positive
patients (several patients had more than one complication)
Complication Number %
Sepsis/infection 8 (30%)
Bone marrow suppression 7 (26%)
Gastric ulcers 2 (7%)
Hyperglycemia 1 (4%)
Shingles 1 (4%)
Avascular necrosis 1 (4%)
The relationship between crescent score and renal func-
tion is shown in Figure 3.
Immunosuppression was begun in 18 patients with
combinations of prednisolone, cyclophosphamide, or aza-
thioprine; 16 received additional plasma exchange, with a
median of 10 exchanges (range 5 to 22). Thirteen of the 17
patients who required dialysis at presentation were im-
munosuppressed. Immunosuppression was complicated
by adverse events in 15 of the patients (Table 3). Only
half the patients who did not require immediate dialysis
were treated with immunosuppression (5 of 8), and they
had a good outcome. Since this was a retrospective review
of patients treated in several hospitals, the reasons for
nontreatment in the remaining patients were not always
clear. Some patients were thought to have another cause
for their acute renal impairment (e.g., interstitial nephri-
tis, acute tubular necrosis), and in some, the physicians
felt the patients did not require immunosuppression.
The clinical outcome is shown in Table 4. No patients
presenting with creatinine over 500 lmol/L or requir-
ing dialysis recovered renal function, despite immuno-
suppression with or without plasma exchange. Patients
presenting with a creatinine of less than 500 lmol/L had
a good prognosis; three progressed to end-stage renal
failure, but the remainder had a median creatinine of
117 lmol/L at last follow-up. The same overall results
are seen even if untreated patients are excluded from the
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Table 4. Outcome of double-positive patients stratified by renal
function at presentation
No. of 1-year 1-year
Creatinine patients patient survival renal survival
<500 lmol/L 7 100% 71%
>500 lmol/L 1 100% 0%
Dialysis-dependent 17 35% 0%
Data not available for two patients.
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Fig. 4. Kaplan Meier patient survival for all patients (points represent
censored patients).
analysis, but very few patients with severe disease were
not treated.
Long-term patient survival is shown in Figure 4.
Patients with pulmonary hemorrhage had significantly
higher mortality, with only 17% surviving, compared
to 60% of those without overt pulmonary hemorrhage.
There was no difference in the demographics of patients
with or without lung disease, renal function at presenta-
tion, or antibody titres (either anti-GBM or ANCA). We
did not see any disease flares during follow-up; however,
our data on this may have been incomplete due to the
dispersion of the patients. One patient received a renal
transplant uneventfully.
Comparing the double-positive patients with patients
with isolated anti-GBM disease treated by us [1], they
were older (median age 66 years vs. 40 years), a higher
proportion needed immediate dialysis (70% vs. 55%),
and a similar proportion had pulmonary hemorrhage
(41% vs. 58%) with a similar increase in mortality. The
titre of anti-GBM antibody was the same (50% vs. 58%).
Patients with both antibodies generally had a marked
systemic inflammatory response (more like patients with
conventional vasculitis), but relatively few had systemic
features of vasculitis (scleritis, rash, neuropathy, etc.).
Limited data were available for patients with anti-
GBM antibodies binding antigens other than the con-
ventional Goodpasture antigen. These patients were a
little younger than those with true double-positive dis-
ease (median age 51), had similar renal dysfunction
at presentation, and a similar range of systemic fea-
tures. They tended to have either a C-ANCA or atypi-
cal pattern of ANCA immunofluorescence, with binding
to both MPO and PR3 antigens with equal titre (me-
dian anti-MPO titre 35%). The anti-GBM antibody did
not bind purified monomeric or dimeric components of
collagenase-solubilized GBM, and hence, was not rec-
ognizing any of the NC1 domains of type IV collagen,
but the precise antigen was not defined. One was HIV
seropositive, one had ANA antibodies detectable, and
none were diabetic. Where performed, immunofluores-
cence of the renal biopsy showed linear staining of the
glomerular basement membrane. Data on outcome was
available on 6 of the patients; those presenting dialysis-
dependent did not recover renal function, although only
two of four were treated with immunosuppression.
DISCUSSION
We have confirmed, in a larger cohort of patients, pre-
vious reports suggesting that up to one third of patients
with circulating anti-GBM antibodies also have ANCA,
usually P-ANCA, specific for MPO [4–8, 10, 11, 12]. Up
to 5% of patients with an initial positive serologic test
for ANCA will also be found to have anti-GBM anti-
bodies. The significance of these findings is demonstrated
by the clinical outcome of such double-positive patients,
since none of those presenting with severe renal failure
recovered renal function despite immunosuppression, of-
ten including plasma exchange. This is in marked contrast
to patients with pure ANCA-related disease (without
anti-GBM antibodies), in whom 75% of those present-
ing dialysis-dependent will recover renal function with
appropriate immunosuppression [15], but similar to the
outcome in pure anti-GBM disease in which renal recov-
ery is rare from severe renal failure [1]. Comparing pa-
tients treated solely in our institution, the lack of recovery
from dialysis dependency compares to those with isolated
anti-GBM disease, in whom only 8% have sustained re-
covery of renal function. Historically, a few authors have
reported some patients recovering renal function from
anti-GBM disease, despite severe renal failure [16, 17,
18], and whether these patients have somewhat different
antibody physicochemical properties, or whether dam-
age was simply very acute and immunosuppression par-
ticularly effective, is not clear. In contrast, 75% of our
patients with isolated ANCA-associated vasculitis requir-
ing dialysis recover renal function when treated with im-
munosuppression, including plasma exchange. Patients in
the current study were not all treated in our institution,
but those who did receive immunosuppression received
high doses of steroids, cyclophosphamide, and the me-
dian number of plasma exchanges was 10. Thus, they did
receive effective treatment. The adverse events in this
patient cohort were similar in nature and extent to those
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seen in immunosuppressed patients with either isolated
antibody.
Previous publications on double-positive patients have
generally been limited to a small number of cases, and
have reported varying responses to therapy [4–10, 12].
One study of 12 patients has reported a better outcome
in patients with MPO-ANCA and anti-GBM antibodies
[11]. In this series, 11 of 12 patients had MPO-ANCA, the
mean age was older than patients with pure anti-GBM
disease, patients had more vasculitic features, but some
patients recovered renal function despite an initial need
for dialysis. A more recent Swedish study in 29 patients
also reported a better outcome in patients with both anti-
GBM antibodies and P-ANCA [12]. These patients had
better overall survival, and more chance of recovering re-
nal function, even when presenting with severe renal fail-
ure. They, too, were older than those with only anti-GBM
antibodies, and their anti-GBM antibodies had slightly
lower affinity and specificity. In this study, in fact, all six
patients who recovered renal function from an initial cre-
atinine of more than 600 lmol/L were double positive
[12]. Why our results are somewhat different is not clear,
since the immunologic phenotype seems similar between
the two groups. It may be that our patients presented
later, or had more severe renal damage at presentation.
Our patients might also have had a slightly different spec-
trum of anti-GBM antibodies (higher affinity, for exam-
ple). It might also be that other studies have included
patients with nontypical anti-GBM antibodies, and some
of these might have a better prognosis (but not from our
limited experience). Therefore, the overall results from
patients with severe renal failure reported in the liter-
ature is somewhat mixed, but these results do indicate
that it is crucial to determine whether any patient pre-
senting with either anti-GBM disease or ANCA-related
vasculitis has the second antibody, as this may determine
outcome and guide treatment.
We have predominantly studied the patients in whom
the anti-GBM antibodies were identical to those found
in the isolated disease. Intriguingly, anti-PR3 antibodies
(C-ANCA) were rarely found in this study, except in pa-
tients with nonconventional anti-GBM antibodies. This
is broadly true of most of the published cases, with very
few patients having a C-ANCA, but where they were
found, patients had similar disease severity to those with
P-ANCA [10, 19, 20]. Possible explanations for the emer-
gence of two autoantibodies include a general loss of im-
mune tolerance, but this is unlikely since (for example) no
patient developed antinuclear antibodies, and it is diffi-
cult to explain the relative selectivity for MPO-ANCA. If
the primary mediator was the formation of anti-GBM an-
tibodies, then it is difficult to explain the development of
ANCA following renal injury. It seems more likely that
patients who develop an ANCA-related illness leading
to glomerular damage subsequently mount an immune
response against the exposed and damaged glomerular
basement membrane. This would explain why a number
of patients develop antibodies against components other
than the alpha 3 chain of type IV collagen. However, it
is unusual that the autoantibodies in an ANCA-related
disease become suppressed as rapidly as was observed
in the double-positive patients, and that the majority has
MPO-ANCA. We did not see any disease flares during the
follow-up period of this study. The data we have avail-
able for patients with nontypical anti-GBM antibodies
and ANCA suggest that this group do differ somewhat,
since they tended to have an atypical ANCA pattern by
immunofluorescence, and both MPO and PR3-ANCA.
In some of these patients it would seem the development
of ANCA were more likely part of a widespread immune
dysregulation—for example, one had ANA and one HIV
infection.
The poor clinical outcome in this series of patients with
both autoantibodies and severe renal failure may reflect
more extensive glomerular damage due to anti-GBM
antibody-mediated mechanisms, in addition to ANCA-
mediated endothelial destruction. Patients with extensive
crescents and high antibody titres did not recover renal
function. The pathologic changes observed generally re-
flected acute damage, with little evidence for ongoing
progressive disease. Interstitial scarring was unusual, and
crescents were cellular rather than fibrotic. Despite this,
the failure of patients to recover renal function when pre-
senting dialysis-dependent suggests that double-positive
patients with severe renal failure should be treated as
for anti-GBM disease. Immunosuppressive therapy can
be withheld unless they have pulmonary hemorrhage or
systemic features. In contrast, patients with less severe
renal failure (creatinine less than 500 lmol/L) responded
well to immunosuppression.
CONCLUSION
Patients with either ANCA-related disease or anti-
GBM disease, whether diagnosed serologically or by re-
nal biopsy, should be tested for the second antibody.
This approach should provide better prognosis and guide
management.
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